{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+Cord+Tumor&page=4", "query": { "condition": "Spinal Cord Tumor", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 165, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+Cord+Tumor&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+Cord+Tumor&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T08:22:34.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00918385", "title": "Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Nilutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 57, "start_date": "2009-05", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 3, "location_summary": "Durham, North Carolina • Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00918385" }, { "nct_id": "NCT02166346", "title": "Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transverse Myelitis", "Neuromyelitis Optica", "Idiopathic Transverse Myelitis", "Myelitis NOS" ], "interventions": [ { "name": "Dalfampridine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2014-02", "completion_date": "2017-01-08", "has_results": true, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02166346" }, { "nct_id": "NCT04721717", "title": "AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Spinal Cord Injuries", "Multiple Sclerosis", "Transverse Myelitis", "Amyotrophic Lateral Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2020-09-01", "completion_date": "2025-04-04", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04721717" }, { "nct_id": "NCT03655223", "title": "Early Check: Expanded Screening in Newborns", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Spinal Muscular Atrophy", "Fragile X Syndrome", "Fragile X - Premutation", "Duchenne Muscular Dystrophy", "Hyperinsulinemic Hypoglycemia, Familial 1", "Diabetes Mellitus", "Adrenoleukodystrophy, Neonatal", "Medium-chain Acyl-CoA Dehydrogenase Deficiency", "Very Long Chain Acyl Coa Dehydrogenase Deficiency", "Beta-ketothiolase Deficiency", "Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency", "Primary Hyperoxaluria Type 1", "Congenital Bile Acid Synthesis Defect Type 2", "Pyridoxine-Dependent Epilepsy", "Hereditary Fructose Intolerance", "Hypophosphatasia", "Hyperargininemia", "Mucopolysaccharidosis Type 6", "Argininosuccinic Aciduria", "Citrullinemia, Type I", "Wilson Disease", "Maple Syrup Urine Disease, Type 1A", "Maple Syrup Urine Disease, Type 1B", "Biotinidase Deficiency", "Neonatal Severe Primary Hyperparathyroidism", "Intrinsic Factor Deficiency", "Usher Syndrome Type 1D/F Digenic (Diagnosis)", "Cystic Fibrosis", "Stickler Syndrome Type 2", "Stickler Syndrome Type 1", "Alport Syndrome, Autosomal Recessive", "Alport Syndrome, X-Linked", "Carbamoyl Phosphate Synthetase I Deficiency Disease", "Carnitine Palmitoyl Transferase 1A Deficiency", "Carnitine Palmitoyltransferase II Deficiency", "Cystinosis", "Chronic Granulomatous Disease", "Cerebrotendinous Xanthomatoses", "Maple Syrup Urine Disease, Type 2", "Severe Combined Immunodeficiency Due to DCLRE1C Deficiency", "Thyroid Dyshormonogenesis 6", "Thyroid Dyshormonogenesis 5", "Supravalvar Aortic Stenosis", "Factor X Deficiency", "Hemophilia A", "Hemophilia B", "Tyrosinemia, Type I", "Fructose 1,6 Bisphosphatase Deficiency", "Glycogen Storage Disease Type I", "G6PD Deficiency", "Glycogen Storage Disease II", "Galactokinase Deficiency", "Mucopolysaccharidosis Type IV A", "Galactosemias", "Guanidinoacetate Methyltransferase Deficiency", "Agat Deficiency", "Glutaryl-CoA Dehydrogenase Deficiency", "Gtp Cyclohydrolase I Deficiency", "Hyperinsulinism-Hyperammonemia Syndrome", "Primary Hyperoxaluria Type 2", "3-Hydroxyacyl-CoA Dehydrogenase Deficiency", "Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency", "Mitochondrial Trifunctional Protein Deficiency", "Sickle Cell Disease", "Beta-Thalassemia", "Holocarboxylase Synthetase Deficiency", "3-Hydroxy-3-Methylglutaric Aciduria", "Primary Hyperoxaluria Type 3", "Hermansky-Pudlak Syndrome 1", "Hermansky-Pudlak Syndrome 4", "Apparent Mineralocorticoid Excess", "HSDB", "CBAS1", "Mucopolysaccharidosis Type 2", "Mucopolysaccharidosis Type 1", "Severe Combined Immunodeficiency, X Linked", "Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency", "Diabetes Mellitus, Permanent Neonatal", "Isovaleric Acidemia", "Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder)", "Jervell and Lange-Nielsen Syndrome 2", "Hyperinsulinemic Hypoglycemia, Familial, 2", "Diabetes Mellitus, Permanent Neonatal, With Neurologic Features", "Jervell and Lange-Nielsen Syndrome 1", "Lysosomal Acid Lipase Deficiency", "CblF", "3-Methylcrotonyl CoA Carboxylase 1 Deficiency", "3-Methylcrotonyl CoA Carboxylase 2 Deficiency", "Waardenburg Syndrome Type 2A", "Methylmalonic Aciduria cblA Type", "Methylmalonic Aciduria cblB Type", "Methylmalonic Aciduria and Homocystinuria Type cblC", "MAHCD", "Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency", "Congenital Disorder of Glycosylation Type 1B", "Mthfr Deficiency", "Methylcobalamin Deficiency Type Cbl G (Disorder)", "Methylcobalamin Deficiency Type cblE", "Usher Syndrome, Type 1B", "N-acetylglutamate Synthase Deficiency", "Ornithine Transcarbamylase Deficiency", "Phenylketonurias", "Waardenburg Syndrome Type 1", "Congenital Hypothyroidism", "Propionic Acidemia", "Usher Syndrome, Type 1F", "Pancreatic Agenesis 1", "Hereditary Hypophosphatemic Rickets", "Glycogen Storage Disease IXB", "Glycogen Storage Disease IXC", "MOWS", "Epilepsy, Early-Onset, Vitamin B6-Dependent", "Pyridoxal Phosphate-Responsive Seizures", "Pituitary Hormone Deficiency, Combined, 1", "Ptsd", "Dihydropteridine Reductase Deficiency", "Severe Combined Immunodeficiency Due to RAG1 Deficiency", "Severe Combined Immunodeficiency Due to RAG2 Deficiency", "Retinoblastoma", "Multiple Endocrine Neoplasia Type 2B", "Pseudohypoaldosteronism, Type I", "Liddle Syndrome", "Biotin-Responsive Basal Ganglia Disease", "SCD", "DIAR1", "GSD1C", "Acrodermatitis Enteropathica", "Thyroid Dyshormonogenesis 1", "Riboflavin Transporter Deficiency", "Waardenburg Syndrome, Type 2E", "SRD", "Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency", "Barth Syndrome", "Adrenocorticotropic Hormone Deficiency", "Transcobalamin II Deficiency", "Thyroid Dyshormonogenesis 3", "Segawa Syndrome, Autosomal Recessive", "Autosomal Recessive Nonsyndromic Hearing Loss", "Thyroid Dyshormonogenesis 2A", "Congenital Isolated Thyroid Stimulating Hormone Deficiency", "Hypothyroidism Due to TSH Receptor Mutations", "Usher Syndrome Type 1C", "Usher Syndrome Type 1G (Diagnosis)", "Von Willebrand Disease, Type 3", "Combined Immunodeficiency Due to ZAP70 Deficiency", "Adenine Phosphoribosyltransferase Deficiency", "Metachromatic Leukodystrophy", "Canavan Disease", "Menkes Disease", "Carbonic Anhydrase VA Deficiency", "Developmental and Epileptic Encephalopathy 2", "17 Alpha-Hydroxylase Deficiency", "Smith-Lemli-Opitz Syndrome", "Krabbe Disease", "Glutathione Synthetase Deficiency", "Mucopolysaccharidosis Type 7", "Rett Syndrome", "Molybdenum Cofactor Deficiency, Type A", "Niemann-Pick Disease, Type C1", "Niemann-Pick Disease Type C2", "Ornithine Aminotransferase Deficiency", "3-Phosphoglycerate Dehydrogenase Deficiency", "Leber Congenital Amaurosis 2", "Dravet Syndrome", "Mucopolysaccharidosis Type 3 A", "Ornithine Translocase Deficiency", "Carnitine-acylcarnitine Translocase Deficiency", "Glucose Transporter Type 1 Deficiency Syndrome", "Creatine Transporter Deficiency", "Niemann-Pick Disease Type A", "Pitt Hopkins Syndrome", "Tuberous Sclerosis 1", "Tuberous Sclerosis 2", "Ataxia With Isolated Vitamin E Deficiency", "Angelman Syndrome", "Prader-Willi Syndrome", "Homocystinuria", "Permanent Neonatal Diabetes Mellitus", "Transient Neonatal Diabetes Mellitus", "Factor VII Deficiency", "Glycogen Storage Disease Type IXA1", "Glycogen Storage Disease, Type IXA2", "Glycogen Storage Disease IC", "Glycogen Storage Disease Type IB", "Central Hypoventilation Syndrome With or Without Hirschsprung Disease" ], "interventions": [ { "name": "Confirmatory Testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "RTI International", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Day", "maximum_age": "31 Days", "sex": "ALL", "summary": "1 Day to 31 Days" }, "enrollment_count": 30000, "start_date": "2018-10-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Research Triangle Park, North Carolina", "locations": [ { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03655223" }, { "nct_id": "NCT06203106", "title": "NYSCF Scientific Discovery Biobank", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "ALS", "Amyotrophic Lateral Sclerosis", "Alzheimer Disease", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Batten Disease", "Corticobasal Degeneration", "Dementia", "Frontotemporal Dementia", "Huntington Disease", "Lewy Body Disease", "Multiple Sclerosis", "Multiple System Atrophy", "Parkinson Disease", "Parkinson's Disease and Parkinsonism", "Progressive Supranuclear Palsy", "INAD", "Diabetes", "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Diabetes Mellitus, Type 1", "Macular Degeneration", "Ovarian Cancer", "Cervical Cancer", "Uterine Cancer", "Vaginal Cancer", "Vulvar Cancer", "PTSD", "Post Traumatic Stress Disorder" ], "interventions": [ { "name": "Biological Sample Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "New York Stem Cell Foundation Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": null, "sex": "ALL", "summary": "30 Days and older" }, "enrollment_count": 10000, "start_date": "2022-11-10", "completion_date": "2045-11-10", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06203106" }, { "nct_id": "NCT05945784", "title": "Exploring Accessible Beauty for Individuals With Upper Extremity Deficits", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke, Ischemic", "Stroke Hemorrhagic", "Stroke (CVA) or TIA", "Stroke, Acute", "Traumatic Brain Injury", "SCI - Spinal Cord Injury", "Ehlers-Danlos Syndromes (EDS)", "Lupus Erythematosus", "Guillain-Barre Syndrome", "Multiple Sclerosis", "Myasthenia Gravis", "Amyotrophic Lateral Sclerosis", "Graves Disease", "Muscular Dystrophies" ], "interventions": [ { "name": "Use of Rare Beauty makeup products", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Casa Colina Hospital and Centers for Healthcare", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 57, "start_date": "2023-07-21", "completion_date": "2023-09-29", "has_results": false, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Pomona, California", "locations": [ { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945784" }, { "nct_id": "NCT04031469", "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gut Microbiome", "Gastrointestinal Microbiome", "Autism", "Autism Spectrum Disorder", "Autism Spectrum Disorder High-Functioning", "Alzheimer Disease", "Alzheimer Dementia (AD)", "Alzheimer Dementia", "Alzheimer Disease (AD)", "Crohn", "Crohn Colitis", "Crohn Disease (CD)", "Crohn Disease Colon", "Myalgic Encephalomyelitis", "ME/CFS", "Myalgic Encephalomyelitis (ME)", "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "Psoriasis", "Psoriasis Annularis", "Psoriasis Chronic", "Chronic Urinary Tract Infection", "Ulcerative Colitis (Disorder)", "Ulcerative Colitis (UC)", "Ulcerative Colitis Acute", "Ulcerative Colitis Chronic", "Multiple Sclerosis", "Multiple Sclerosis (MS) - Relapsing-remitting", "Multiple Sclerosis (MS) Primary Progressive", "Constipation Chronic Idiopathic", "Constipation", "Celiac", "Celiac Disease", "Celiac Sprue", "Lyme Arthritis", "Lyme Borreliosis, Nervous System", "Lyme Disease, Chronic", "Cholesterol", "Cholesterol Level, High", "Cancer", "Colon Cancer", "Amyotrophic Lateral Sclerosis (ALS)", "Amyotrophic Lateral Sclerosis", "Rheumatoid Arthritis (RA)", "Rheumatoid Arthritis - Rheumatism", "Chronic Fatigue Syndrome (CFS)", "PARKINSON DISEASE (Disorder)", "Parkinson Disease", "Parkinson Disease (PD)", "Depression", "Major Depressive Disorder (MDD)", "Depression Disorder", "Depression in Adults", "Anxiety", "Anxiety Disorder Generalized", "Obsessive Compulsive Disorder (OCD)", "Obsessive Compulsive Disorder OCD", "Obsessive - Compulsive Disorder", "Bipolar", "Bipolar 1 Disorder", "Bipolar Disorder (BD)", "Bipolar Disorder I and II", "Bipolar and Related Disorders", "Migraine", "Migraine Disorder", "Diabetes (DM)", "Diabetes", "Lupus", "Lupus Erythematosus", "Epidermolysis Bullosa (EB)", "Mesothelioma", "Mesothelioma Malignant", "IBS (Irritable Bowel Syndrome)", "Irritable Bowel", "IBS - Irritable Bowel Syndrome", "Irritable Bowel Syndrome (IBS)", "Eczema", "Eczema Atopic Dermatitis", "Acne", "Myasthaenia Gravis", "Gout" ], "interventions": [ { "name": "There is no intervention in this study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1000, "start_date": "2019-07-11", "completion_date": "2030-12-10", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04031469" }, { "nct_id": "NCT00381797", "title": "Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Cerebral Anaplastic Astrocytoma", "Childhood Oligodendroglioma", "Childhood Spinal Cord Neoplasm", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 97, "start_date": "2006-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 11, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381797" }, { "nct_id": "NCT01407341", "title": "Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Spinal Cord Neoplasm", "Spinal Bone Metastases", "Spinal Cord Compression" ], "interventions": [ { "name": "musculoskeletal complications management/prevention", "type": "PROCEDURE" }, { "name": "bone graft", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2011-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407341" }, { "nct_id": "NCT04708431", "title": "Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Androgen Insensitivity Syndrome", "Metabolic Parameters in AIS, CAIS, PAIS and MAIS", "Tumor Formation in AIS, CAIS, PAIS and MAIS", "Sexual Function AIS, CAIS, PAIS and MAIS" ], "interventions": [], "intervention_types": [], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "8 Years to 99 Years" }, "enrollment_count": 650, "start_date": "2021-04-29", "completion_date": "2040-02-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-05T08:22:34.473Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04708431" } ] }